pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

5,218 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1825Endpoints1414Fierce Biotech736BioSpace725BioPharma Dive537raps241onclive165fda recalls
therapy area
allOncology12558Rare Disease3279Immunology2962Cardiology2832Hematology2224Pulmonology2201Vaccines
  • AAMC leadership stays vigilant after midterm shift, urges continued congressional support for research
    The Association of American Medical Colleges gathered about 4,100 educators, researchers, clinicians and trainees at its annual meeting in Anaheim, California, a short walk from Disneyland. AAMC C…
    STAT · 2h agoRegulatoryNeutral↗ source
  • Sofinnova Partners raises €725 million for second crossover fund targeting late-stage European biotech firms
    Sofinnova Partners announced the closing of its second crossover fund with €725 million ($815 million) in commitments. The fund is designed to fill the financing gap for late-stage European biopha…
    Endpoints · 4h agoDealPositive↗ source
← prev
page 1 of 209
next →
116
fda medwatch112
globenewswire health73
fda press59
1821
Psychiatry & CNS1224
Ophthalmology1087
Endocrinology & Metabolism788
Pain784
Nephrology767
  • Emerging biotech hubs like India could help lower global drug costs by scaling development
    The article notes that every new therapy raises two core questions: can it be created and can society afford it. Historically biotech has focused on the first question. The author argues that as s…
    BioSpace · 6h agoNeutral↗ source
  • Biopharma firms showcase non-amyloid Alzheimer’s strategies at CTAD 2026 conference
    Biopharma companies including Biogen, Bristol Myers Squibb and Roche gathered in Boston for the Clinical Trials on Alzheimer’s Disease (CTAD) 2026 conference, where they presented new data on their…
    BioSpace · 6h agoPositive↗ source
  • Novartis and BMS pause autoimmune CAR-T trials after patient deaths and safety concerns
    Novartis, Bristol Myers Squibb and several other biotech firms have recently encountered setbacks while developing therapies for autoimmune diseases. Some programs have been completely discontinued…
    BioSpace · 6h agoNegative readoutNegative↗ source
  • Chinese authorities dismiss two researchers after child dies in gene‑editing study
    Chinese authorities have dismissed two researchers involved in a gene‑editing study after a child participant died. State media reported the firings, showing the government's swift response to the…
    Fierce Biotech · 7h agoRegulatoryNegative↗ source
  • Tandem Diabetes Care gets FDA clearance for tubeless insulin delivery system with up to 7-day wear
    Tandem Diabetes Care announced that the FDA has cleared its Tandem Mobi system as a tubeless automated insulin delivery device. The clearance allows the device to be worn for up to seven days witho…
    Fierce Biotech · 9h agoRegulatoryPositive↗ source
  • BeOne Medicines and Hengrui Lead STAT-WireScreen’s China Biotech Powerhouse 25 Ranking
    STAT and risk‑intelligence platform WireScreen have published a new ranking called China’s Biotech Powerhouse 25, which lists the most valuable publicly traded biotech companies in the country. Th…
    STAT · 2h agoNeutral↗ source
  • Physician burnout persists as hospitals push self-care instead of systemic fixes
    In a new STAT+ column, former ENT surgeon Frances Mei Hardin reflects on the growing crisis of physician burnout and the limited impact of hospital‑mandated wellness programs. Hardin shares a pers…
    STAT · 2h agoNegative↗ source
  • BridgeBio's Morgan Paull and Christine Zhang Named BioSpace 40 Under 40, Emphasize Patient-Centric Model
    BridgeBio has seen two of its young executives, Morgan Paull and Christine Zhang, named to BioSpace’s 2026 40 Under 40 list. Their inclusion highlights the company’s rapid growth and focus on rare-…
    BioSpace · 6h agoPositive↗ source
  • Apple and OpenEvidence Begin Study of Experimental AI Health Chat App
    Apple and OpenEvidence have launched a study centered on an experimental AI-powered health chat application. The pilot allows users to link personal health data to the chatbot, which then provides…
    STAT · 10h agoNeutral↗ source
  • Kennedy's MAHA Initiative Gains Momentum with Stephen Miller as White House Chief of Staff
    Stephen Miller's recent appointment as White House chief of staff has been described as a catalyst for the health secretary's MAHA agenda. The move appears to have energized the initiative, accordi…
    STAT · 2h agoPositive↗ source
  • CLINUVEL to cut up to 20% of staff and move headquarters to New York
    CLINUVEL announced a strategic reorganization aimed at focusing resources on the U.S. market. The company will reduce its global workforce by 10% to 20%, affecting up to 21 of its 104 employees.…
    BioSpace · 9h agoLayoffsNegative↗ source
  • Proposal to start medical school after Step 1 exam to cut debt and boost diversity
    The authors, bioethicists at SUNY Upstate Medical University, argue that medical education should be split into two distinct phases. The first phase would cover the pre‑clinical sciences that are t…
    STAT · 2h agoPositive↗ source
  • STAT+: Versant, Lilly put $100 million behind new startup aimed at solving one of gene therapy’s thorniest issues
    Versant Ventures, Eli Lilly, and a handful of other investors will pour $100 million into a new startup devoted to solving a thorny gene therapy challenge.
    STAT · 1h ago↗ source
  • Seawolf surfaces with $100M, $1.2B Sanofi pact for redosable DNA medicines
    Backed by Novartis’ venture arm, El Lilly and CRISPR Therapeutics, Seawolf is advancing its nonviral DNA delivery platform while inking a pact with Sanofi.
    BioSpace · 1h ago↗ source
  • Seawolf launches with $100M to make non-viral gene therapies
    A San Diego startup believes it’s made big progress in one of the great unsolved technical challenges of the gene therapy field: safely and effectively delivering DNA without a virus. Seawolf Thera…
    Endpoints · 1h ago↗ source
  • FDA denies Summit Therapeutics' ivonescimab for EGFR-mutated lung cancer, halting US entry
    The U.S. Food and Drug Administration issued a complete response letter rejecting Summit Therapeutics' biologics license application for ivonescimab, a PD-1xVEGF bispecific antibody intended for EG…
    BioSpace · 21h agoCRLNegative↗ source
  • FDA rejects Summit and Akeso's ivonescimab for narrow lung cancer
    The U.S. Food and Drug Administration has turned down ivonescimab, a new cancer therapy being developed by Summit Therapeutics and Akeso, for use in a specific type of lung cancer. Analysts had la…
    Endpoints · 22h agoRegulatoryNegative↗ source
  • STAT+: FDA rejects lung cancer treatment ivonescimab from Summit Therapeutics
    The FDA has rejected ivonescimab, a treatment for a type of lung cancer developed by U.S. biotech Summit Therapeutics and the Chinese drugmaker Akeso.
    STAT · 20h ago↗ source
  • George Church departs AI startup as Ira Mellman advances immunotherapy efforts
    The latest Endpoints Weekly notes that geneticist George Church has left the artificial-intelligence startup he co-founded, signaling a shift in his focus. The newsletter also highlights that immu…
    Endpoints · 2d agoNeutral↗ source
  • PharmaLogic acquires Lantheus radiopharma CDMO and New Jersey plant to launch transatlantic manufacturing platform
    PharmaLogic announced it will purchase Lantheus' radiopharmaceutical contract development and manufacturing organization (CDMO) along with a production plant in Springfield, New Jersey. Lantheus h…
    BioSpace · 2d agoDealNeutral↗ source
  • Moderna says it is ready to produce thousands of doses of its Merck-partnered cancer vaccine ahead of FDA filing
    Moderna announced that it is on track to manufacture large quantities of a cancer vaccine developed in partnership with Merck. The company says production facilities are prepared to produce thousa…
    Endpoints · 2d agoRegulatoryPositive↗ source
  • FDA issues complete response letter, rejecting Summit Therapeutics' ivonescimab for EGFR-mutated lung cancer
    The U.S. Food and Drug Administration sent a complete response letter to Summit Therapeutics, declining to approve its bispecific antibody ivonescimab for patients with previously treated EGFR‑muta…
    Fierce Biotech · 2d agoRegulatoryNegative↗ source
  • Takeda narcolepsy pill receives DEA clearance as Oura-Lilly deal raises conflict concerns and Pfizer exits Canadian Premarin market
    Takeda announced that its experimental narcolepsy medication has been cleared by the U.S. Drug Enforcement Administration, marking the first regulatory nod for a therapy aimed at treating excessive…
    STAT · 2d agoRegulatoryPositive↗ source